CTC Dx Firm Biocept Posts 23 Percent Increase in 2013 Revenues | GenomeWeb

NEW YORK (GenomeWeb News) – Oncology diagnostics company Biocept said on Friday that its revenues for 2013 increased 23 percent year over year.

For full-year 2013, revenues rose to $134,245 from $109,289 in 2012, the San Diego-based firm said in its Form 10-K filed with the US Securities and Exchange Commission. Its net loss in 2013 was $9.2 million, or $50.80 per share, compared to a net loss of $12.3 million, or $76.43 per share, in 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.